Spyre raises $180m to advance IBD antibody pipeline

At the start of this year, Aeglea BioTherapeutics was looking like it may go out of business. Now, rebranded as Spyre Therapeutics, it is looking to the future with a new chief executive and another $180 million in private financing from existing and new backers.